These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 12774694

  • 1. Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes.
    Hu B, Jennings LL.
    Prog Med Chem; 2003; 41():167-94. PubMed ID: 12774694
    [No Abstract] [Full Text] [Related]

  • 2. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
    Weyer C, Gautier JF, Danforth E.
    Diabetes Metab; 1999 Mar; 25(1):11-21. PubMed ID: 10335419
    [Abstract] [Full Text] [Related]

  • 3. Recent developments in the design of orally bioavailable beta3-adrenergic receptor agonists.
    Sawa M, Harada H.
    Curr Med Chem; 2006 Mar; 13(1):25-37. PubMed ID: 16457637
    [Abstract] [Full Text] [Related]

  • 4. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans.
    de Souza CJ, Burkey BF.
    Curr Pharm Des; 2001 Sep; 7(14):1433-49. PubMed ID: 11472270
    [Abstract] [Full Text] [Related]

  • 5. Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.
    Moore MC.
    Curr Opin Investig Drugs; 2006 Oct; 7(10):924-35. PubMed ID: 17086938
    [Abstract] [Full Text] [Related]

  • 6. Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.
    Lafontaine JA, Day RF, Dibrino J, Hadcock JR, Hargrove DM, Linhares M, Martin KA, Maurer TS, Nardone NA, Tess DA, Dasilva-Jardine P.
    Bioorg Med Chem Lett; 2007 Sep 15; 17(18):5245-50. PubMed ID: 17632003
    [Abstract] [Full Text] [Related]

  • 7. All in one: Researchers create combination drugs for diabetes and obesity.
    Chakradhar S.
    Nat Med; 2016 Jul 07; 22(7):694-6. PubMed ID: 27387879
    [No Abstract] [Full Text] [Related]

  • 8. Antiobesity and antidiabetic beta-agonists: lessons learned and questions to be answered.
    Yen TT.
    Obes Res; 1994 Sep 07; 2(5):472-80. PubMed ID: 16353599
    [Abstract] [Full Text] [Related]

  • 9. American Diabetes Association--69th Scientific sessions. Obesity management and treatment of type 2 diabetes: Part 1.
    Kouremenou C.
    IDrugs; 2009 Aug 07; 12(8):463-4. PubMed ID: 19629873
    [No Abstract] [Full Text] [Related]

  • 10. Prodrugs of CL316243: a selective beta3-adrenergic receptor agonist for treating obesity and diabetes.
    Sum FW, Gilbert A, Venkatesan AM, Lim K, Wong V, O'Dell M, Francisco G, Chen Z, Grosu G, Baker J, Ellingboe J, Malamas M, Gunawan I, Primeau J, Largis E, Steiner K.
    Bioorg Med Chem Lett; 1999 Jul 19; 9(14):1921-6. PubMed ID: 10450954
    [Abstract] [Full Text] [Related]

  • 11. [beta 3-adrenergic receptor agonists as anti-obese and anti-diabetic drugs].
    Sakura H, Togashi M, Iwamoto Y.
    Nihon Rinsho; 2002 Jan 19; 60(1):123-9. PubMed ID: 11808322
    [Abstract] [Full Text] [Related]

  • 12. New options for drug treatment of obesity in patients with Type 2 diabetes.
    Kennedy RL, Khoo EY.
    Diabet Med; 2005 Sep 19; 22 Suppl 4():23-6. PubMed ID: 16109016
    [No Abstract] [Full Text] [Related]

  • 13. Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.
    Feng DD, Biftu T, Candelore MR, Cascieri MA, Colwell LF, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.
    Bioorg Med Chem Lett; 2000 Jul 03; 10(13):1427-9. PubMed ID: 10888324
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and evaluation of N-phenyl-(2-aminothiazol-4-yl)acetamides with phenoxypropanolamine moiety as selective β3-adrenergic receptor agonists.
    Maruyama T, Onda K, Suzuki T, Hayakawa M, Takahashi T, Matsui T, Takasu T, Nagase I, Ohta M.
    Chem Pharm Bull (Tokyo); 2012 Jul 03; 60(5):647-58. PubMed ID: 22689403
    [Abstract] [Full Text] [Related]

  • 15. Diabetes knowledge and its importance expands rapidly: diabetes update in clinical therapeutics.
    Ryan JG.
    Clin Ther; 2013 Jan 03; 35(1):A1-2. PubMed ID: 23328272
    [No Abstract] [Full Text] [Related]

  • 16. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS.
    Cardiovasc Res; 2018 Aug 01; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract] [Full Text] [Related]

  • 17. Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.
    Biftu T, Feng DD, Liang GB, Kuo H, Qian X, Naylor EM, Colandrea VJ, Candelore MR, Cascieri MA, Colwell LF, Forrest MJ, Hom GJ, MacIntyre DE, Stearns RA, Strader CD, Wyvratt MJ, Fisher MH, Weber AE.
    Bioorg Med Chem Lett; 2000 Jul 03; 10(13):1431-4. PubMed ID: 10888325
    [Abstract] [Full Text] [Related]

  • 18. Leapin' lizards: Amylin targets diabetes and obesity via incretins.
    Wolfson W.
    Chem Biol; 2007 Mar 03; 14(3):235-6. PubMed ID: 17379135
    [No Abstract] [Full Text] [Related]

  • 19. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D, Prasad-Reddy L, Srivastava SB.
    Am J Health Syst Pharm; 2016 Oct 01; 73(19):1493-507. PubMed ID: 27521241
    [Abstract] [Full Text] [Related]

  • 20. Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
    Maruyama T, Seki N, Onda K, Suzuki T, Kawazoe S, Hayakawa M, Matsui T, Takasu T, Ohta M.
    Bioorg Med Chem; 2009 Aug 01; 17(15):5510-9. PubMed ID: 19581100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.